Sensei Biotherapeutics Stock EBITDA
| SNSE Stock | USD 0.53 0.07 11.67% |
Sensei Biotherapeutics fundamentals help investors to digest information that contributes to Sensei Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Sensei Stock. The fundamental analysis module provides a way to measure Sensei Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sensei Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -33.4 M | -35.1 M |
Sensei | EBITDA |
Sensei Biotherapeutics Company EBITDA Analysis
Sensei Biotherapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Sensei Biotherapeutics EBITDA | (33.39 M) |
Most of Sensei Biotherapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sensei Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sensei EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Sensei Biotherapeutics is extremely important. It helps to project a fair market value of Sensei Stock properly, considering its historical fundamentals such as EBITDA. Since Sensei Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sensei Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sensei Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Sensei Ebitda
Ebitda |
|
According to the company disclosure, Sensei Biotherapeutics reported earnings before interest,tax, depreciation and amortization of (33.39 Million). This is 103.8% lower than that of the Biotechnology sector and 133.33% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.86% higher than that of the company.
Sensei EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sensei Biotherapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sensei Biotherapeutics could also be used in its relative valuation, which is a method of valuing Sensei Biotherapeutics by comparing valuation metrics of similar companies.Sensei Biotherapeutics is currently under evaluation in ebitda category among its peers.
Sensei Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Sensei Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sensei Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sensei Biotherapeutics' value.| Shares | Cresset Asset Management, Llc | 2024-09-30 | 19.7 K | Two Sigma Securities, Llc | 2024-06-30 | 18.6 K | Xtx Topco Ltd | 2024-09-30 | 13.9 K | Deuterium Capital Management, Llc | 2024-06-30 | 11 K | Blackrock Inc | 2024-06-30 | 7.8 K | Tower Research Capital Llc | 2024-06-30 | 7.1 K | Jpmorgan Chase & Co | 2024-06-30 | 748 | Royal Bank Of Canada | 2024-06-30 | 247 | Bank Of America Corp | 2024-06-30 | 139 | Ikarian Capital, Llc | 2024-09-30 | 650 K | Vanguard Group Inc | 2024-09-30 | 618.8 K |
Sensei Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (27.44 M) | ||||
| Shares Outstanding | 25.15 M | ||||
| Shares Owned By Insiders | 34.39 % | ||||
| Shares Owned By Institutions | 8.81 % | ||||
| Number Of Shares Shorted | 194.69 K | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | (33.39 M) | ||||
| Net Income | (34.1 M) | ||||
| Cash And Equivalents | 123.71 M | ||||
| Cash Per Share | 4.03 X | ||||
| Total Debt | 6.21 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 23.46 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (32.02 M) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 4.13 | ||||
| Number Of Employees | 28 | ||||
| Beta | 0.059 | ||||
| Market Capitalization | 15.09 M | ||||
| Total Asset | 74.37 M | ||||
| Retained Earnings | (231.9 M) | ||||
| Working Capital | 61.61 M | ||||
| Net Asset | 74.37 M |
About Sensei Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sensei Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sensei Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sensei Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sensei Biotherapeutics is a strong investment it is important to analyze Sensei Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sensei Biotherapeutics' future performance. For an informed investment choice regarding Sensei Stock, refer to the following important reports:Check out Sensei Biotherapeutics Piotroski F Score and Sensei Biotherapeutics Altman Z Score analysis. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.